Dapagliflozin Plus Pioglitazone in T1DM
Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Mar 15, 2019
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a new combination therapy for people with Type 1 Diabetes Mellitus (T1DM). The researchers want to see if adding two medications, dapagliflozin and pioglitazone, to a patient’s insulin treatment can help improve blood sugar control without increasing the risk of serious side effects, like ketoacidosis (a dangerous condition caused by high ketone levels) or low blood sugar. The study will include 120 healthy adults aged 18 and older who struggle to manage their blood sugar levels despite using insulin.
Participants in the trial will first go through a 4-week period to assess their health, followed by 12 weeks of taking dapagliflozin. After that, they will be randomly assigned to receive either pioglitazone or a placebo (a treatment that looks like the real drug but has no active ingredients) for an additional 16 weeks. During the study, researchers will monitor participants' blood sugar levels and overall health using various tests. This trial is currently recruiting participants, and eligible individuals should have specific criteria, such as poor blood sugar control and a stable insulin dose. If you're interested or think you might qualify, it’s a good idea to talk to your healthcare provider for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years
- • T1DM
- • Good general health
- • Fasting C-peptide concentration \<0.7 ng/ml
- • Poor glycemic control (HbA1c=7.0-11.0%)
- • Treatment with multiple daily insulin injections or insulin pump
- • Total daily insulin dose ≥0.6 U/kg per day
- • Stable insulin dose (±4 units) in the preceding three months.
- • eGFR≥60 ml/min
- • Weight stable over the preceding 3 months (± 3 pounds)
- • Do not participate in an excessively heavy exercise program
- Exclusion Criteria:
- • T2DM
- • Daily insulin dose \<0.6 U/kg per day
- • Fasting C-peptide \>0.7 ng/ml
- • HbA1c \<7.0% or \>11.0%
- • eGFR\<60 ml/min
- • Hematuria in urine analysis
- • Pregnancy, lactating, positive pregnancy test or planning to become pregnant in the following year.
- • Women of child-bearing potential will be requested to use at least two barrier methods before being enrolled in the study.
- • Major organ system disease which includes: (i) malignancy or history of malignancy including bladder cancer; (ii) Congestive heart failure or history of coronary heart disease or any other cardiac disease; (iii) chronic liver disease or LFT \>3 times the upper normal level; (iv) History of alcohol or drug abuse; (v) History of chronic lung disease (e.g., COPD, asthma); (vi) history of rheumatic disease; (vii) History of chronic pancreatitis or pancreatic surgery; (viii) History of CVA or TIA (ix) Planned surgery during the study; (x) history of HIV infection or other immune compromised disease; and history of organ transplantation; (xi) patients who take medications, other than insulin, known to affect glucose metabolism, e.g., prednisone.
- • Evidence of proliferative diabetic retinopathy
- • Patients enrolled in a heavy exercise program
- • Patients on ketogenic diet
- • History of hospitalization for DKA, hypoglycemia or uncontrolled hyperglycemia in the preceding 6 month.
- • Presence of symptoms of poor glycemic control, e.g. polydipsia or polyurea
- • History of hypersensitivity to dapagliflozin or pioglitazone
About The University Of Texas Health Science Center At San Antonio
The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is a leading academic medical institution dedicated to advancing health through education, research, and patient care. As a prominent sponsor of clinical trials, UT Health San Antonio focuses on innovative medical research aimed at improving health outcomes across diverse populations. With a commitment to excellence, the institution fosters collaboration among its multidisciplinary teams to explore cutting-edge therapies and interventions. Through rigorous scientific inquiry and ethical practices, UT Health San Antonio strives to make meaningful contributions to the field of medicine and enhance the quality of life for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Antonio, Texas, United States
Kuwait City, , Kuwait
Haifa, , Israel
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials